These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 28159656)
1. Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole. Qi F; Zhu L; Li N; Ge T; Xu G; Liao S Int J Antimicrob Agents; 2017 Apr; 49(4):403-409. PubMed ID: 28159656 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19. Zvyaga T; Chang SY; Chen C; Yang Z; Vuppugalla R; Hurley J; Thorndike D; Wagner A; Chimalakonda A; Rodrigues AD Drug Metab Dispos; 2012 Sep; 40(9):1698-711. PubMed ID: 22648560 [TBL] [Abstract][Full Text] [Related]
3. In vitro study of the variable effects of proton pump inhibitors on voriconazole. Niece KL; Boyd NK; Akers KS Antimicrob Agents Chemother; 2015 Sep; 59(9):5548-54. PubMed ID: 26124167 [TBL] [Abstract][Full Text] [Related]
4. A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations. Blanco Dorado S; Maroñas Amigo O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A Br J Clin Pharmacol; 2020 Aug; 86(8):1661-1666. PubMed ID: 32110830 [TBL] [Abstract][Full Text] [Related]
5. Effect of proton pump inhibitor on plasma voriconazole concentration in Thai patients. Chayakulkeeree M; Poovipirom N; Siengwattana P; Maneerattanaporn M J Med Assoc Thai; 2015 Mar; 98(3):232-7. PubMed ID: 25920292 [TBL] [Abstract][Full Text] [Related]
6. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. Frelinger AL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Brooks JK; Bhatt DL; Michelson AD J Am Coll Cardiol; 2012 Apr; 59(14):1304-11. PubMed ID: 22464259 [TBL] [Abstract][Full Text] [Related]
7. Predicting the Effects of Different Triazole Antifungal Agents on the Pharmacokinetics of Tamoxifen. Chen L; Zhu L; Li M; Li N; Qi F; Wang N AAPS PharmSciTech; 2019 Jan; 20(1):24. PubMed ID: 30604153 [TBL] [Abstract][Full Text] [Related]
8. The impact of proton pump inhibitors on the pharmacokinetics of voriconazole in vitro and in vivo. Yan M; Wu ZF; Tang D; Wang F; Xiao YW; Xu P; Zhang BK; Liu YP; Xiang DX; Banh HL Biomed Pharmacother; 2018 Dec; 108():60-64. PubMed ID: 30216801 [TBL] [Abstract][Full Text] [Related]
9. Agreement of Different Drug-Drug Interaction Checkers for Proton Pump Inhibitors. Carollo M; Crisafulli S; Selleri M; Piccoli L; L'Abbate L; Trifirò G JAMA Netw Open; 2024 Jul; 7(7):e2419851. PubMed ID: 38980677 [TBL] [Abstract][Full Text] [Related]
10. Effect of proton pump inhibitors on voriconazole concentrations in Chinese patients with malignant hematological diseases. Huang Q; Liu Q; Yin T; Hu L; Ding H; Liu S; Jiang Y Eur J Clin Pharmacol; 2020 Jun; 76(6):833-842. PubMed ID: 32157329 [TBL] [Abstract][Full Text] [Related]
11. Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers. Funck-Brentano C; Szymezak J; Steichen O; Ducint D; Molimard M; Remones V; Azizi M; Gaussem P Arch Cardiovasc Dis; 2013 Dec; 106(12):661-71. PubMed ID: 24246616 [TBL] [Abstract][Full Text] [Related]
12. Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer. Lau YY; Gu W; Lin T; Viraswami-Appanna K; Cai C; Scott JW; Shi M Cancer Chemother Pharmacol; 2017 Jun; 79(6):1119-1128. PubMed ID: 28424965 [TBL] [Abstract][Full Text] [Related]
13. Assessment of drug-drug interactions between voriconazole and glucocorticoids. Li M; Zhu L; Chen L; Li N; Qi F J Chemother; 2018 Sep; 30(5):296-303. PubMed ID: 30843777 [TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Robinson M; Horn J Drugs; 2003; 63(24):2739-54. PubMed ID: 14664653 [TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo evaluation of drug-drug interaction between dabigatran and proton pump inhibitors. Ollier E; Hodin S; Basset T; Accassat S; Bertoletti L; Mismetti P; Delavenne X Fundam Clin Pharmacol; 2015 Dec; 29(6):604-14. PubMed ID: 26392328 [TBL] [Abstract][Full Text] [Related]
16. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Ogilvie BW; Yerino P; Kazmi F; Buckley DB; Rostami-Hodjegan A; Paris BL; Toren P; Parkinson A Drug Metab Dispos; 2011 Nov; 39(11):2020-33. PubMed ID: 21795468 [TBL] [Abstract][Full Text] [Related]
17. Prediction of the effect of voriconazole on the pharmacokinetics of non-steroidal anti-inflammatory drugs. Li N; Zhu L; Qi F; Li M; Xu G; Ge T J Chemother; 2018 Jul; 30(4):240-246. PubMed ID: 30375950 [TBL] [Abstract][Full Text] [Related]
18. Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors? Clark DW; Strandell J Eur J Clin Pharmacol; 2006 Jun; 62(6):473-9. PubMed ID: 16758264 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Wedemeyer RS; Blume H Drug Saf; 2014 Apr; 37(4):201-11. PubMed ID: 24550106 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of possible pharmacokinetic interaction between methotrexate and proton pump inhibitors in rats. Ueda H; Narumi K; Sato Y; Furugen A; Kobayashi M; Iseki K Pharmacol Rep; 2020 Oct; 72(5):1426-1432. PubMed ID: 32671657 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]